Sanofi Aktie

79,37 EUR -0,42 EUR -0,53 %

07:47:46

FSE

72,01 CHF -3,47 CHF -4,60 %

12.02.2026

BRX

Sanofi jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.99,80 Mrd. EUR

KGV12,92

WKN920657

ISINFR0000120578

SymbolSNYNF

Sanofi Aktien News

Sortieren:Datum Meistgelesen

27.06.23GlobeNewswirePress Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody

25.06.23GlobeNewswirePress Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing

22.06.23GlobeNewswirePress Release: Availability of the Q2 2023 Memorandum for modelling purposes

20.06.23GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - May 2023

20.06.23GlobeNewswirePress Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim

13.06.23GlobeNewswirePress Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients

08.06.23GlobeNewswirePress Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants

01.06.23GlobeNewswirePress Release: Sanofi launches 2023 global Employee Stock Purchase Plan

31.05.23GlobeNewswirePress Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis

25.05.23GlobeNewswirePress Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors

21.05.23GlobeNewswirePress Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

17.05.23GlobeNewswireSanofi: Information concerning the total number of voting rights and shares – April 2023

12.05.23GlobeNewswirePress Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

04.05.23GlobeNewswireSanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTS

27.04.23GlobeNewswirePress Release: Sanofi completes acquisition of Provention Bio, Inc.

27.04.23GlobeNewswirePress Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC

26.04.23GlobeNewswirePress Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.

19.04.23GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - March 2023

11.04.23GlobeNewswirePress Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements

10.04.23GlobeNewswirePress Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.

04.04.23PR NewswireSanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines

04.04.23GlobeNewswirePress Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia

30.03.23GlobeNewswirePress Release: Availability of the Q1 2023 Memorandum for modelling purposes

23.03.23GlobeNewswirePress Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

21.03.23GlobeNewswirePress Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

18.03.23GlobeNewswirePress Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

16.03.23GlobeNewswirePress Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

14.03.23GlobeNewswireInformation concerning the total number of voting rights and shares – February 2023

13.03.23GlobeNewswirePress Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

07.03.23GlobeNewswirePress Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

02.03.23GlobeNewswirePress Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A

24.02.23GlobeNewswireALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)

24.02.23GlobeNewswirePress release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease

23.02.23GlobeNewswirePress Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

15.02.23GlobeNewswireSanofi: Information concerning the total number of voting rights and shares – January 2023

13.02.23GlobeNewswirePress Release: Sanofi announces change in R&D leadership

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.